Form 4 for BIIB Biogen
Accepted 2023-04-04 00:00:00 ET · period of report 2023-03-31 · accession 0001127602-23-012361 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-04 | 2023-03-31 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +239 | 5,818 | +4% | $0 |
| D | 2023-04-04 | 2023-03-31 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $278.03 | -116 | 5,702 | -2% | -$32.3K |
| D | 2023-04-04 | 2023-03-31 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | -239 | 240 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-31 | M | A | 239 | $0.00 | 5,818.29 | D | — | — | (F1) Includes 91.6992 shares acquired under the Biogen Inc. employee stock purchase plan. |
| 2 | Common | Common Stock | 2023-03-31 | F | D | 116 | $278.03 | 5,702.29 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2023-03-31 | M | D | 239 | $0.00 | 240 | D | $0.00 · — to 2024-04-01 | 239 Common Stock | (F2) This award was granted to the reporting person on April 1, 2021. The remaining portion of the award vests in equal installments on each of the second and third anniversary of the grant date. |